Application of Jianpi Xiaoai Recipe Combined with Cisplatin and Adriamycin in the Treatment of Endometrial Cancer and Its Effect on Disease Control Rate.

Li Ding,Hongyu Li,Yuping Wang

doi:10.1155/2021/2258183

Abstract

Objective To explore the application of Jianpi Xiaoai recipe combined with cisplatin and Adriamycin in the treatment of endometrial cancer (EC) and its effect on the disease control rate (DCR). Methods The data of 120 EC patients treated in People's Hospital of Rizhao from February 2019 to February 2020 were retrospectively analyzed. They were equally split into experimental group and control group according to the order of admission. All patients were treated with neoadjuvant intra-arterial chemotherapy (continuous infusion of the uterine artery for 5 days before surgery, with 20 mg of cisplatin mixed with 2000 mg of normal saline and 10 mg of Adriamycin mixed with 500 ml of normal saline daily), while the experimental group was treated with Jianpi Xiaoai recipe at the same time to compare the short-term efficacy, immune function indexes, incidence of adverse reactions, and HEC-1-B (human endometrial adenocarcinoma cells) cell inhibition rates between the two groups. Results The DCR and objective remission rate (ORR) in the experimental group were markedly higher compared with the control group (P < 0.05). The immune function indexes after treatment were remarkably better in the experimental group than in the control group (P < 0.05). Compared with the control group, the incidence of adverse reactions in the experimental group was notably lower (P < 0.05), while the HEC-1-B inhibition rates after treatment were obviously higher (P < 0.05). Conclusion Jianpi Xiaoai recipe combined with cisplatin and Adriamycin can increase the HEC-1-B cell inhibition rate in EC patients, improve their immune function, reduce the possibility of adverse reactions, and enhance the therapeutic effect, which is worthy of clinical application and popularization.

Highlights

Endometrial cancer (EC) is an epithelial malignant tumor that occurs in the endometrium
endometrial cancer (EC) is a female reproductive systemic malignant tumor with the incidence second only to cervical cancer [16], which is common in perimenopausal women. e early symptoms of EC are nonspecific, and patients may present with symptoms such as abnormal leukorrhea and lumbar-abdominal pain as the disease progresses, seriously threatening their life health
Neoadjuvant intraarterial chemotherapy is often adopted in the treatment of gynecological malignancies such as cervical cancer, which has been proven to inhibit the proliferative activity of cancer cells and accelerate their apoptosis [19]

Summary

Introduction

Endometrial cancer (EC) is an epithelial malignant tumor that occurs in the endometrium. Sugandha et al found that based on the conventional chemotherapy regimens, dialectical application of Jianpi Xiaoai recipe can increase the disease control rate (DCR) of patients with advanced metastatic colorectal cancer and reduce the possibility of adverse reactions [11]. From the perspective of modern pharmacology, Jianpi Xiaoai recipe can play a significant role in the treatment of EC because its components such as ginseng, Astragalus, poria, progesterone, and ginsenoside Rg3 can regulate the immune function of patients and block the iron transport pathways of human endometrial adenocarcinoma cells (HEC-1-B), inducing apoptosis of cancer cells by inhibiting HEC-1-B and enhancing the therapeutic effect [12]. From the perspective of modern pharmacology, Jianpi Xiaoai recipe can play a significant role in the treatment of EC because its components such as ginseng, Astragalus, poria, progesterone, and ginsenoside Rg3 can regulate the immune function of patients and block the iron transport pathways of human endometrial adenocarcinoma cells (HEC-1-B), inducing apoptosis of cancer cells by inhibiting HEC-1-B and enhancing the therapeutic effect [12]. erefore, this paper combined Jianpi Xiaoai recipe with cisplatin and Adriamycin to explore the application effect on EC patients, reported as follows

Methods

Results

Conclusion